Facts
Myelodysplastic syndrome (MDS) involves abnormal production of blood cells in your bone marrow.
Fred Hutchinson Cancer Center offers comprehensive treatment from a team of experts who specialize in MDS and related diseases.
Following the merger of long-time partners, Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, the organization was renamed to Fred Hutchinson Cancer Center. We are an independent, nonprofit organization that also serves as UW Medicine's cancer program.
What is MDS?
MDS is not a single disease but a group of diseases that affect blood-cell formation. In all subtypes of MDS, a chronic bone marrow problem leads to low levels of blood cells circulating in your bloodstream.
- “Myelo” refers to bone marrow, which is the body’s blood-cell factory.
- “Dysplastic” refers to abnormal growth or development.
- “Myelodysplastic” means the bone marrow produces abnormal blood cells.
To understand more about MDS, it’s helpful to understand the basics of how blood cells normally form.
Frequently asked questions
Subtypes
Doctors divide MDS into subtypes based on:
- Whether you have increased numbers of blast cells in your bone marrow or blood and what percentage of your marrow or blood is made up of blasts
- Whether your marrow shows abnormal growth in only one type of blood cell (unilineage dysplasia) or in more than one type of blood cell (multilineage dysplasia)
- Whether your marrow cells have chromosome abnormalities and, if so, which type or types
Doctors also look at the surface markers of MDS cells to see whether the cells express certain antigens. Antigens are substances that the immune system recognizes. Researchers at Fred Hutch pioneered the process of detecting MDS cells by flow cytometry and developing models based on surface markers to help diagnose the disease and predict the outcome.
These and other factors, such as any other health problems you have, may help your doctor decide which treatment options make the most sense for you and how aggressive your treatment should be.
Learn about subtypes
Here is a list of MDS subtypes, according to the World Health Organization system of MDS classification.
Some problems with blood-cell formation are not only myelodysplastic (having to do with abnormal production of cells in the marrow) or only myeloproliferative (having to do with overproduction of cells in the marrow). Instead, these problems have features of both MDS and myeloproliferative neoplasms.
Symptoms
In the early stages of MDS, many people have no symptoms. But a routine blood test may show low levels of RBCs, WBCs or platelets.
Some people have symptoms related to their low blood counts. These can range from mild to severe and can vary greatly from one person to another.
Other conditions besides MDS can cause the same symptoms. If you have these symptoms, see your doctor to find the cause.
Diagnosing
To find out whether you have MDS, your doctor will do a thorough physical exam and ask about your health history and any symptoms. You will also have:
- Blood tests — to check how many cells of each type are in your blood (complete blood count), how the cells look (peripheral blood smear) and whether they have certain abnormalities (blood chemistry).
- Bone marrow aspiration and biopsy — using a needle to take small samples of your marrow. A pathologist examines the samples under a microscope to look for and count abnormal cells. This provides a definitive diagnosis.
- Cytogenetic analysis — tests of your marrow to look for chromosome abnormalities that help predict how your disease will progress and which types of treatment might be most effective.
Prognosis and staging
For cancer, doctors typically use a system called staging to determine how early or advanced a person’s disease is (stage I for early cancer to stage IV for advanced cancer).
MDS has a different type of staging system. Doctors classify the disease using the Revised International Prognostic Scoring System (IPSS-R). Your IPSS-R score helps your doctor determine how fast your disease is likely to progress (your prognosis).
Your score is based on:
- The percentage of blasts in your bone marrow (less than 5 percent, 5 to 10 percent, 11 to 20 percent, or 21 to 30 percent)
- Which, if any, chromosome abnormalities are present in your marrow cells (categorized as good, intermediate or poor)
- The severity of your cytopenias (low blood counts, meaning low RBCs, WBCs and platelets)
Your score tells your doctor which risk group you are in: very low, low, intermediate, high or very high.
These risk groups are only estimates for groups of people. Your risk group is meant to give you and your doctor an idea of what might happen for you based on what usually happens for people whose MDS is similar to yours. Your score doesn’t predict the exact outlook for you as an individual.